Fresh analysis reveals that individuals who discontinue popular weight-loss injections like semaglutide or tirzepatide may regain reduced body mass far faster than those who end conventional lifestyle programs.
Research printed in a major medical journal shows that while obese individuals often shed about a fifth of their total mass while using the jabs, the weight returns at an estimated rate of 0.8 kg per month once they quit.
"Users buying these medications should be aware of the risk of rapid rebound weight gain when the treatment ends," warns lead investigator Dr. Susan Jebb.
That rate of recovery suggests a reversion to pre-treatment weight in about 18 months.
Analyzing Therapies
The analysis, which examined 37 of studies involving over 9,000 of patients, compared the outcomes of these new drugs with conventional dieting.
Researchers emphasize that individuals who lose weight through diet and exercise typically see a less rapid creep back—approximately 0.1 kg a month—after stopping.
Understanding the Fast Rebound
Doctors suggest the mechanism of the drugs is key to understanding the accelerated rebound.
The injections mimic a body's own chemical called GLP-1, which helps regulate appetite.
"Long-term administration of the hormone levels several times higher than normal may cause the body to produce less of its endogenous hormone, and could reduce responsiveness to its effects," noted Dr. Adam Collins, a nutrition expert.
"Discontinuation of this GLP-1 'fix' results in appetite is uncontrolled, making excessive eating far more likely."
A Lifelong Issue?
Health authorities recommend the injections for individuals with obesity-related health risks, accompanied by prescribed lifestyle changes.
Professionals say that, considering the likelihood of relapse, the treatment is often ongoing.
This opinion is reinforced by drug manufacturers, who say that the findings "highlight the long-term nature of obesity," akin to managing conditions like diabetes.
User Experiences
Individuals who have discontinued the medication explain a intense resurgence of hunger.
"I experienced something flipping and you're instantly ravenous," described one woman.
This challenge is exacerbated if individuals have not adopted sustainable lifestyle or habit changes during therapy.
Growing Adoption
Recent estimates indicate that a significant number of adults in the UK have tried these injections in the past year, with demand continuing to grow.
- Use is higher among women than men.
- The 40s and 50s age group shows the greatest usage rates.
- A large proportion access the medications through private healthcare rather than public health services.
In conclusion, experts emphasize that while GLP-1 drugs are potent tools for shedding pounds, they are not a standalone solution and long-term success hinges on combined behavioural management.
